Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 121 results
A minimalist representation of a single cell and gene strands in a dark palette.

Jul 28, 2026

Novogene Europe Adds Single-Cell Sequencing at Cambridge Omics Centre

Novogene Europe has enhanced its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, providing advanced sequencing services to researchers in the UK.This development leverages Novogene's established expertise in single-cell technologies, integrating specialized project support, sequencing infrastructure, and bioinformatics analysis. The aim is to facilitate deeper biological insights from complex samples, responding to the increasing demand for accessible single-cell transcrip
Illustration of a single cell with RNA strands

Jul 27, 2026

Novogene Europe Adds Single-Cell Sequencing at Cambridge Omics Centre

Novogene Europe has enhanced its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, making advanced sequencing workflows more accessible to researchers in the UK.This expansion leverages Novogene's expertise in single-cell analysis, integrating specialized project support, sequencing technologies, and bioinformatics to facilitate deeper biological insights from complex samples. The service addresses the increasing demand for single-cell transcriptomics, enabling researchers t
A minimalist representation of a base editor and DNA strand in a dark color scheme.

Jul 25, 2026

AlphaFold AI redesigns gene-editing proteins to enhance safety, and biotech investors should pay attention

A new AI framework named ContactSeek, built on the advancements of AlphaFold3, is set to revolutionize gene-editing technologies by enhancing their safety and precision. This innovation is particularly significant for biotech investors and stakeholders in the field of gene therapy.ContactSeek addresses a critical challenge in gene editing: the risk of unintended DNA cuts. By utilizing AlphaFold3's structural predictions, the framework allows researchers to redesign base editors—molecular tools t
Petri dish with cultured human cells in a dim laboratory setting

Jul 22, 2026

The biotech bi-weekly: multiomics, human cell-based research, next-gen cell recovery and biomarker development

This week in biotech highlights significant advancements in multiomics, human cell research, and innovative production methods involving microbes.Novogene Europe has bolstered its multiomics capabilities with the launch of an Untargeted Metabolomics Service at its Cambridge Omics Centre. This service aims to enhance the understanding of molecular interactions by integrating metabolomic data with genomics and other life sciences, providing researchers with deeper insights into biological function
A minimalist illustration of a DNA strand representing genomic testing.

Jul 22, 2026

Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership

Tempus AI is set to acquire Personalis, a cancer genomics testing firm, in a strategic move valued at approximately $1.5 billion. This acquisition aims to enhance Tempus AI's capabilities in the rapidly expanding minimal residual disease (MRD) testing market, projected to be worth $20 billion.Under the terms of the agreement, Tempus AI will purchase all outstanding shares of Personalis at $16.25 each, reflecting a premium over recent stock prices. The deal is primarily an all-stock transaction,
A genome sequencing sample in a clinical setting with an MRI machine in the background.

Jul 12, 2026

Whole Genome Interpretation Services

Simplify Genomics and SimonMed have joined forces to enhance preventive healthcare through a novel integration of whole genome interpretation and advanced MRI technology.This collaboration leverages Simplify Genomics' expertise in whole genome analysis, supported by its CAP/CLIA-certified platform that has processed over 50,000 genomes. This platform not only identifies numerous disease associations but also provides pharmacogenomic insights. On the other hand, SimonMed contributes its extensive
A minimalist representation of a test tube with an aptamer inside, symbolizing molecular diagnostics.

Jul 12, 2026

En Carta Diagnostics secures 5 million euros for home testi

En Carta Diagnostics has successfully raised 5 million euros to enhance its molecular testing capabilities for Lyme disease and sexually transmitted infections (STIs), focusing on both the US and European markets.The Paris-based startup secured 3 million euros in equity funding led by Blue Forest Ventures, with contributions from Ring Capital and others, alongside an additional 2 million euros in non-dilutive funding from Bpifrance. Founded in 2022, En Carta aims to develop home-based diagnostic
A stack of banknotes on a lab countertop with equipment in the background

Jul 9, 2026

Alchemab extends Series A with £25m from British Business Bank

Alchemab has successfully secured an additional £25 million in funding from the British Business Bank, marking a significant milestone as it represents the largest direct investment in life sciences by the bank to date. This investment aligns with the UK’s strategic efforts to retain high-growth biotech firms within its borders.Previously, Alchemab raised £60 million in its initial Series A round in 2021, which was intended to propel its initiatives in neurodegeneration and cancer therapies. The
Silhouette of a computational biologist with a magnifying glass against a solid background.

Jul 8, 2026

Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform

Lantern Pharma has unveiled ZetaOmics, an innovative AI-driven computational biology platform designed to enhance cancer research through advanced bioinformatics.This new module, part of the company's multi-agentic AI co-scientist platform withZeta.ai, features an autonomous agent termed the “Computational Biologist.” This agent is engineered to conduct comprehensive bioinformatics and multi-omic analyses across diverse cancer types. Initially accessible via an early-access program for select co
Silhouette of DNA strand and droplet representing liquid biopsy

Jul 7, 2026

Strand Life Sciences Bags Patent for AI Cancer Detection Tech

Strand Life Sciences has achieved a significant milestone by securing an Indian patent for its innovative AI-driven blood test aimed at early cancer detection.This technology leverages advanced genome sequencing and machine learning techniques to analyze cell-free DNA from blood samples, enabling the identification of cancer markers. Developed at Strand's Bengaluru facility, the method incorporates complex biological processes such as methylation profiling and fragmentomics to enhance detection
A minimalist illustration of a blood droplet and DNA strand

Jul 7, 2026

Reliance's Strand Life Sciences Secures Indian Patent

Reliance Industries' subsidiary, Strand Life Sciences, has achieved a significant milestone by securing an Indian patent for an innovative AI-driven blood test aimed at early-stage cancer detection.The patent, granted on July 7, 2026, pertains to a platform that utilizes cell-free DNA analysis. This advanced technology integrates high-quality genome sequencing with machine learning techniques to extract critical features, including methylation and fragmentomic data, from a single blood sample. T
A test tube with a blood sample in a dimly lit lab setting.

Jul 7, 2026

Reliance-Backed Strand Life Sciences bags Indian patent for AI-powered blood test to detect cancer early

Strand Life Sciences, a subsidiary of Reliance Industries, has secured a patent for an innovative AI-driven blood test aimed at early cancer detection.The newly patented technology leverages artificial intelligence and cell-free DNA (cfDNA) analysis to identify early cancer indicators from a simple blood sample. By integrating advanced genome sequencing with machine learning algorithms, the platform can detect significant DNA methylation changes—an established cancer marker—while maintaining cri